suPAR and prediction and treatment of acute kidney injury
Inventors
Reiser, Jochen • Hayek, Salim • Quyyumi, Arshed A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12492250-B2
Publication Date
2025-12-09
Expiration Date
Abstract
Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.
Core Innovation
The invention relates to a method of treating or reducing the incidence or severity of acute kidney injury induced by a contrast agent in a human patient by using soluble urokinase plasminogen activator receptor (suPAR) as a measure and treatment trigger. The method comprises measuring or having measured a level of suPAR in a biological sample from a human patient exposed to a contrast agent and determining or having determined that the level of suPAR is about 3 ng/ml or greater.
Based on this suPAR level, a therapeutically effective amount of an anti-suPAR antibody or an antigen-binding fragment thereof is administered to reduce the incidence or severity of acute kidney injury induced by the contrast agent. The disclosure positions the approach as specifically targeting suPAR with an anti-suPAR antibody or antigen-binding fragment that specifically binds to suPAR in the context of contrast-agent exposure.
Claims Coverage
The provided claim coverage identifies one independent claim directed to treating or reducing the incidence or severity of contrast-agent induced acute kidney injury using suPAR measurement followed by administration of an anti-suPAR antibody or antigen-binding fragment that specifically binds to suPAR. The inventive features focus on measuring suPAR in a biological sample, applying a suPAR threshold of about 3 ng/ml or greater, and administering a therapeutically effective amount of the anti-suPAR antibody or antigen-binding fragment to the human patient.
Measuring suPAR in a biological sample from a human patient exposed to a contrast agent
The method includes measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the human patient exposed to a contrast agent.
Determining a suPAR level threshold of about 3 ng/ml or greater
The method determines or having determined that the level of suPAR in the sample is about 3 ng/ml or greater.
Administering an anti-suPAR antibody or antigen-binding fragment that specifically binds to suPAR
The method administers a therapeutically effective amount of an anti-suPAR antibody or an antigen-binding fragment thereof that specifically binds to suPAR to the human patient to reduce the incidence or severity of acute kidney injury induced by the contrast agent.
The core inventive combination is suPAR-based patient stratification and therapeutic administration of an anti-suPAR antibody or antigen-binding fragment that specifically binds to suPAR to reduce the incidence or severity of contrast-agent induced acute kidney injury.
Stated Advantages
Reducing the incidence or severity of acute kidney injury induced by the contrast agent.
Documented Applications
Treating or reducing the incidence or severity of acute kidney injury induced by a contrast agent in a human patient.
Risk context includes contrast-induced nephropathy (CIN) in conjunction with contrast exposure.
Interested in licensing this patent?